ArticleTranslational vision science & technology2025
Comparing Myopia Control Effects of Three Different Orthokeratology Lenses and Spectacle Lenses With Highly Aspherical Lenslets in Low Myopia Children.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Short-Term Effects of Orthokeratology Treatment Zone Decentration on Choroidal Thickness and Vasculature.Translational vision science & technology · 2026Article
- A personalized simulation framework for optimizing orthokeratology lens parameters based on 3D corneal modeling and biomechanical analysis.Frontiers in bioengineering and biotechnology · 2026Article
- Comparison of myopia control efficacy between single vision and highly aspherical Lenslet spectacle lenses in children with low myopia: a 1-year retrospective study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the effectiveness of three different orthokeratology (OK) lenses and highly aspherical-lenslet spectacle lenses (HAL) for myopia control in young children with low myopia, and to compare the relative corneal refractive power (RCRP) distributions among the three OK lenses with different designs. Methods: This retrospective study involved 166 children aged eight to 11 years with myopia of -0.50 to -3.00 D treated with ProTong OK lenses with aspheric base curve (APOK), ProTong OK lenses with spherical base curve (SPOK), Euclid OK lenses (EOK), HAL, or single-vision spectacle lenses (SVL). Axial length (AL) was measured at baseline and the 12-month visit. Corneal topography was measured for OK wearers to determine the distance from the apex RCRP profile to its three-quarter-peak. Results: The axial elongation for the APOK, SPOK, HAL, EOK, and SVL groups were 0.17 ± 0.14 mm, 0.25 ± 0.17 mm, 0.11 ± 0.15 mm, 0.37 ± 0.12 mm, and 0.45 ± 0.16 mm after 12 months, respectively. Axial elongation was significantly slower for the APOK, SPOK, and HAL groups than for the EOK or SVL groups (all P < 0.05); and it was significantly slower in HAL than in SPOK wearers (P < 0.05). 59.5% and 42.9% of HAL and APOK wearers experienced axial elongation of ≤0.15 mm, respectively. The HAL and APOK, SPOK and APOK, or EOK and SVL groups showed no significant differences in axial elongation. Both SPOK and APOK groups had lower 3/4X values than the EOK group. Conclusions: HAL and APOK wear, relative to EOK or SVL wear, by eight- to 11-year-old children with low myopia led to comparable yet slower axial elongation. APOK and SPOK led to a steeper distribution of the RCRP profile within the pupillary range and yielded better myopia control than EOK. Translational Relevance: HAL and APOK are recommended for effective myopia control in children aged eight to 11 years with mild myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.